Article Abstract

The use of transcatheter mitral valve system: can we make mitral regurgitation better again?

Authors: Mohammed A. Chamsi-Pasha, Stephen H. Little, Michael J. Reardon

Abstract

Percutaneous treatments of valvular heart disease have evolved over the past two decades. These “minimally invasive” procedures are attractive alternatives to surgery for a growing high-risk population with multiple comorbidities. In 2002, Cribier et al. (1) performed the first transcatheter aortic valve implantation (TAVI) in a patient with aortic stenosis. Currently, TAVI has become a common procedure for high or prohibitive surgical risk patient and is moving rapidly into intermediate risk patients, with over 250,000 devices implanted worldwide.